CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ENCANT develops biocompatible nanoparticles to enhance external beam radiotherapy for cancer treatment. By improving targeting and reducing radiation doses, the project aims to increase patient survival rates and minimize side effects, particularly for prostate cancer, while allowing adaptability for other tumor types.
Current cancer research efforts are focused on obtaining targeted therapies, with greater precision, that lead to improved patient survival, with fewer adverse effects to ensure a better quality of life. ENCANT (nanoengineered particles for ENhanced CANcer radioTherapy) will contribute to this aim by developing new therapeutic agents based on biocompatible nanoparticles bearing high atomic number (Z) elements, which will enhance external beam radiotherapy (EBRT) effect on cancer tissue.
This wil…
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE
Spain, Barcelona
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
